122 related articles for article (PubMed ID: 32705365)
1. Sensitivity to differential NRF1 gene signatures contributes to breast cancer disparities.
Ramos J; Yoo C; Felty Q; Gong Z; Liuzzi JP; Poppiti R; Thakur IS; Goel R; Vaid AK; Komotar RJ; Ehtesham NZ; Hasnain SE; Roy D
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2777-2815. PubMed ID: 32705365
[TBL] [Abstract][Full Text] [Related]
2. Nuclear respiratory factor 1 transcriptomic signatures as prognostic indicators of recurring aggressive mesenchymal glioblastoma and resistance to therapy in White American females.
Bhawe K; Das JK; Yoo C; Felty Q; Gong Z; Deoraj A; Liuzzi JP; Ehtesham NZ; Hasnain SE; Singh VP; Mohapatra I; Komotar RJ; Roy D
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1641-1682. PubMed ID: 35441887
[TBL] [Abstract][Full Text] [Related]
3. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract][Full Text] [Related]
4. Nuclear Respiratory Factor 1 (NRF1) Transcriptional Activity-Driven Gene Signature Association with Severity of Astrocytoma and Poor Prognosis of Glioblastoma.
Bhawe K; Felty Q; Yoo C; Ehtesham NZ; Hasnain SE; Singh VP; Mohapatra I; Roy D
Mol Neurobiol; 2020 Sep; 57(9):3827-3845. PubMed ID: 32594352
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor of DNA Binding Protein 3 (ID3) and Nuclear Respiratory Factor 1 (NRF1) Mediated Transcriptional Gene Signatures are Associated with the Severity of Cerebral Amyloid Angiopathy.
Perez CM; Gong Z; Yoo C; Roy D; Deoraj A; Felty Q
Mol Neurobiol; 2024 Feb; 61(2):835-882. PubMed ID: 37668961
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas.
Huo D; Hu H; Rhie SK; Gamazon ER; Cherniack AD; Liu J; Yoshimatsu TF; Pitt JJ; Hoadley KA; Troester M; Ru Y; Lichtenberg T; Sturtz LA; Shelley CS; Benz CC; Mills GB; Laird PW; Shriver CD; Perou CM; Olopade OI
JAMA Oncol; 2017 Dec; 3(12):1654-1662. PubMed ID: 28472234
[TBL] [Abstract][Full Text] [Related]
7. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.
Warner ET; Tamimi RM; Hughes ME; Ottesen RA; Wong YN; Edge SB; Theriault RL; Blayney DW; Niland JC; Winer EP; Weeks JC; Partridge AH
J Clin Oncol; 2015 Jul; 33(20):2254-61. PubMed ID: 25964252
[TBL] [Abstract][Full Text] [Related]
8. Impact of molecular subtype and race on HR+, HER2- breast cancer survival.
Reid S; Haddad D; Tezak A; Weidner A; Wang X; Mautz B; Moore J; Cadiz S; Zhu Y; Zheng W; Mayer IA; Shu XO; Pal T
Breast Cancer Res Treat; 2021 Oct; 189(3):845-852. PubMed ID: 34331630
[TBL] [Abstract][Full Text] [Related]
9. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
Troester MA; Sun X; Allott EH; Geradts J; Cohen SM; Tse CK; Kirk EL; Thorne LB; Mathews M; Li Y; Hu Z; Robinson WR; Hoadley KA; Olopade OI; Reeder-Hayes KE; Earp HS; Olshan AF; Carey LA; Perou CM
J Natl Cancer Inst; 2018 Feb; 110(2):176-82. PubMed ID: 28859290
[TBL] [Abstract][Full Text] [Related]
10. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
11. Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race/Ethnicity in the US From 2010 to 2016.
Acheampong T; Kehm RD; Terry MB; Argov EL; Tehranifar P
JAMA Netw Open; 2020 Aug; 3(8):e2013226. PubMed ID: 32804214
[TBL] [Abstract][Full Text] [Related]
12. Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy.
Lindner R; Sullivan C; Offor O; Lezon-Geyda K; Halligan K; Fischbach N; Shah M; Bossuyt V; Schulz V; Tuck DP; Harris LN
PLoS One; 2013; 8(11):e71915. PubMed ID: 24260093
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.
Keenan T; Moy B; Mroz EA; Ross K; Niemierko A; Rocco JW; Isakoff S; Ellisen LW; Bardia A
J Clin Oncol; 2015 Nov; 33(31):3621-7. PubMed ID: 26371147
[TBL] [Abstract][Full Text] [Related]
14. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups.
Kurian AW; Fish K; Shema SJ; Clarke CA
Breast Cancer Res; 2010; 12(6):R99. PubMed ID: 21092082
[TBL] [Abstract][Full Text] [Related]
15. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
Parise C; Caggiano V
Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
[TBL] [Abstract][Full Text] [Related]
16. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
17. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.
Chen L; Li CI
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1666-72. PubMed ID: 26464428
[TBL] [Abstract][Full Text] [Related]
18. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
[TBL] [Abstract][Full Text] [Related]
19. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
[TBL] [Abstract][Full Text] [Related]
20. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
